Next Article in Journal
Cellular Players in the Herpes Simplex Virus Dependent Apoptosis Balancing Act
Next Article in Special Issue
Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies
Previous Article in Journal
Defective Interfering RNAs: Foes of Viruses and Friends of Virologists
Previous Article in Special Issue
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies
Viruses 2009, 1(3), 920-938; doi:10.3390/v1030920
Article

Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines

1,#, 2,#, 2, 2, 3, 4, 3, 2,5 and 1,6,7,*
Received: 5 October 2009; in revised form: 6 November 2009 / Accepted: 9 November 2009 / Published: 10 November 2009
(This article belongs to the Special Issue AIDS Vaccine)
Download PDF [580 KB, uploaded 11 November 2009]
Abstract: Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5-immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.
Keywords: HIV-1; SHIV; adenovirus; helper-dependent vector; mucosal challenge; serotype-switching HIV-1; SHIV; adenovirus; helper-dependent vector; mucosal challenge; serotype-switching
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Weaver, E.A.; Nehete, P.N.; Nehete, B.P.; Buchl, S.J.; Palmer, D.; Montefiori, D.C.; Ng, P.; Sastry, K.J.; Barry, M.A. Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses 2009, 1, 920-938.

AMA Style

Weaver EA, Nehete PN, Nehete BP, Buchl SJ, Palmer D, Montefiori DC, Ng P, Sastry KJ, Barry MA. Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses. 2009; 1(3):920-938.

Chicago/Turabian Style

Weaver, Eric A.; Nehete, Pramod N.; Nehete, Bharti P.; Buchl, Stephanie J.; Palmer, Donna; Montefiori, David C.; Ng, Philip; Sastry, K. Jagannadha; Barry, Michael A. 2009. "Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines." Viruses 1, no. 3: 920-938.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert